These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17475962)

  • 1. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
    Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
    J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
    de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
    J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
    J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
    Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer.
    Han EJ; Yang YJ; Park JC; Park SY; Choi WH; Kim SH
    Nucl Med Commun; 2015 Dec; 36(12):1187-94. PubMed ID: 26375438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
    Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
    J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Predictive Value of Early In-Treatment
    Usmanij EA; Natroshvili T; Timmer-Bonte JNH; Oyen WJG; van der Drift MA; Bussink J; Geus-Oei LF
    J Nucl Med; 2017 Aug; 58(8):1243-1248. PubMed ID: 28336778
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.